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Abstract
Macrophage migration inhibitory factor (MIF) is a ubiquitously expressed pro-inflammatory
mediator that has also been implicated in the process of oncogenic transformation and tumor
progression. We used a genetic approach to show that deletion of the MIF gene in mice has several
major consequences for the proliferative and transforming properties of cells. MIF-deficient cells
exhibit increased resistance to oncogenic transformation. The transformation defects associated
with MIF deficiency can be overcome through concomitant inactivation of the p53 and Rb/E2F
tumor suppressor pathways. We have produced compelling evidence that the effects of MIF on cell
survival and tumorigenesis are mediated through overlapping pathways, wherein MIF and p53
functionally antagonize each other in the cell. However, the involvement of MIF in p53 function is
secondary to p53-independent mechanisms controlling protein stability, DNA damage checkpoints,
and the integrity of the genome. Given the broad spectrum of cell types that normally express MIF
and its elevated levels at sites of chronic inflammation, this pathway may be generic for many early
stage tumors.
Background
Chronic inflammation and neoplastic transformation are
closely associated, since it is well established that an
increased cancer risk exists in chronically inflamed tissues.
Classic examples include ulcerative colitis-associated
colorectal cancer [1,2], viral hepatitis-associated hepato-
cellular carcinoma [3], and Helicobacter pylori-associated
gastric cancer [4]. Another example is provided by MALT
lymphoma, where chronic infection causes persistent B-
cell activation culminating in chromosomal rearrange-
ments that lead to cancer [5]. It is thought that inflamma-
tion stimulates the formation of tumors through a
mechanism involving the microenvironment and sur-
rounding inflammatory cells [6,7]. However, the precise
molecular links between inflammation and tumor devel-
opment are not fully understood. Macrophage migration
inhibitory factor (MIF) is a ubiquitously expressed pro-
inflammatory mediator that has also been implicated in
the process of oncogenic transformation and tumor pro-
gression [8]. Recent insights into the mechanistic basis of
MIF action show that its interaction with Jab1/CSN5 is of
crucial importance for the proper functioning of DNA
damage response pathways [9]. By interfering with Jab1/
CSN5, MIF controls the neddylation status of cullins and
thereby the activity of SCF ubiquitin ligases. Here, we dis-
cuss the mechanisms by which MIF affects the ubiquitin-
proteasome system, and how this impacts on the integrity
of the genome and on cancer.
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Discussion
MIF serves as a link between inflammation and cancer
Macrophage migration inhibitory factor was originally
identified for its ability to inhibit the random migration
of macrophages in vitro [10,11]. Subsequent work defined
MIF as a potent cytokine with mitogenic and pro-inflam-
matory functions [12]. Recent efforts to identify a cellular
surface receptor for MIF showed that the CD74/CD44
receptor complex mediates binding of extracellular MIF
[13,14]. However, the process by which extracellular MIF
may exert its effect on target cells is still poorly understood
[15].
MIF is remarkably well conserved, and its homologues are
encoded in evolutionarily divergent species, including dif-
ferent vertebrates, worms, insects and plants [16]. For a
cytokine, MIF is unusual, since it is abundantly expressed
by various cell types [12] and stored within the cytoplasm
[17]. Early evidence suggesting a role for MIF in cell
growth and/or differentiation came from the observations
of its expression in developing mouse embryos. The MIF
gene is expressed at early embryonic stages prior to
implantation [18]. At mid-gestation, MIF's expression pat-
tern parallels tissue specification and organogenesis
[19,20]. At later developmental stages, MIF expression is
broadly associated with cellular differentiation [21].
However, MIF appears to be dispensable for normal
development, because MIF-null mice reproduce and grow
normally [22,23].
Traditionally, the major focus of MIF research has been on
its role as a pro-inflammatory mediator within the
immune system. Recent studies, however, showed that
MIF's functional repertoire is not limited to the immune
response, but also extends to the regulation of apoptosis
and malignant transformation. MIF overexpression has
been observed in various human cancer tissues, including
colorectal, breast, lung, bladder and prostate cancer [24-
28]. Genetic studies demonstrated that MIF promotes B-
cell lymphomagenesis and intestinal tumorigenesis in
mice [24,29]. Importantly, MIF overexpression in several
cell types confers resistance to apoptosis through interfer-
ence with the activity of the p53 tumor suppressor [30].
Conversely, when MIF is lost, cell survival and functions
are compromised in a p53-dependent manner [23,31].
Inhibition of MIF expression also phenocopies loss of
hypoxia inducing factor-1α (HIF-1α), a well established
target of p53 regulation, and induces premature senes-
cence [32]. It was hypothesized that upregulation of MIF
at sites of chronic inflammation might impair p53-
dependent cellular responses towards DNA damage and
inappropriate proliferation and, thus, promote the accu-
mulation of oncogenic mutations [30].
In agreement with this, we recently showed that in a
mouse model of Burkitt's lymphoma (Eμ-Myc transgenic
mouse), loss of MIF expression coincides with the induc-
tion of a p53-dependent proliferative block, which pro-
foundly affects normal B-cell development [29].
Moreover, inhibited S-phase progression and subsequent
differentiation block are at the root of the predisposition
of MIF-deficient B-cells to undergo spontaneous p53-
dependent apoptosis. Accordingly, almost all lymphomas
that arise in MIF-deficient Eμ-Myc mice can be accounted
for by mutations within the ARF-p53 axis, indicating that
the p53 pathway is the main determinant for tumor sup-
pression in this model system [29].
However, several observations suggest that the functional
role of MIF in tumorigenesis is more complex than previ-
ously appreciated. In contrast to the notion of MIF as
tumor promoter, two reports have indicated that aber-
rantly low levels of MIF in human tumors could also cor-
relate with poor clinical prognosis and that subcellular
compartimentalization of MIF may likewise be relevant
[33,34]. Our own evidence from chemical one-stage skin
carcinogenesis experiments revealed that deletion of the
MIF gene may lead to increased rates of tumor formation
in mice (Fig. 1). These findings are also supported by
MIF loss promotes skin tumorigenesis Figure 1
MIF loss promotes skin tumorigenesis. 6–10 week old 
male MIF-/- or MIF+/+ C57Bl/6 mice (n = 20 per group) were 
treated with 200 μg of the carcinogen benzo[α]pyrene 
(B[α]P) in 100 μl acetone topically on their backs once per 
week for 20 weeks. Skin tumors started to appear after week 
14, and increased in number during the course of B[α]P 
treatment. MIF-/- mice developed nearly twice as many 
tumors per mouse as MIF+/+ controls. Based on histological 
evaluation by a blinded pathologist, this primarily reflected an 
increase of non-invasive tumors. By contrast, the number of 
invasive tumors was similar between the genotypes. Like-
wise, we found no significant difference with respect to 
tumor size or vascularization. * = statistically significant with 
p < 0.01 in a Student's t-test.
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recent experiments using MIF-knockout mice in a p53-
null background, which showed that MIF deficiency leads
to a shift in the tumor spectrum: while the expected high
frequency of T-cell lymphomas and fibrosarcomas was
reduced upon MIF deficiency, the frequency of B-cell lym-
phomas and carcinomas was strongly increased. Moreo-
ver, the shift in the tumor spectrum led to decreased
survival of MIF-/-p53-/- mice compared to the p53-/- con-
trols [9]. Thus, MIF is unlikely to have sufficient prognos-
tic value when used in isolation from other possible
mutations, particularly those affecting p53.
MIF interacts with Jab1/CSN5
Progression through the cell cycle depends on timely acti-
vation of cyclin-dependent kinases (CDKs), which act in
conjunction with their corresponding cyclins. The protein
levels of cyclins, CDK inhibitors and other major regula-
tory proteins are quantitatively controlled by the ubiqui-
tin-proteasome system (UPS). Which protein is
ubiquitylated and subsequently degraded relies on recog-
nition by two principal E3 ubiquitin ligases, the ana-
phase-promoting/cyclosome complex (APC/C) and the
Skp1-Cullin1-F-box (SCF) complex. These protein com-
plexes appear to fulfill related but nonetheless distinct
functions in the regulation of the cell cycle, as SCFs are
active from late G1 to early M-phase, whereas the APC/C
is activated from mid M-phase to the end of G1-phase
[35]. The SCF complex has recently taken center stage in
regulatory biology because it links extra- and intracellular
signals to destruction of various proteins by the proteas-
ome [36,37]. Thus, SCFs target many key proteins
involved in the control of normal cell division, such as
cyclin E, c-Jun, c-Myc, p21, p27, β-catenin and Notch [38-
44]. Recent work shows that the SCF complex is also a
central effector of DNA damage and repair pathways act-
ing in the S- and G2M-phases of the cell cycle [45,46].
Therefore, it is not surprising that SCF is frequently a tar-
get of genetic alteration in cancer [37], and that deregu-
lated SCF activity greatly promotes cancer development
[47].
The SCF complex is made of four components, wherein
Rbx1, Cul1 (scaffold protein) and Skp1 (adaptor protein)
are invariable subunits. The fourth component, the F-box
protein, serves as a substrate recognition unit. Given the
variety of F-box proteins that can be recruited to the SCF
complex (more than 70 F-box proteins have been identi-
fied in humans), the functional diversity of the SCF com-
plex appears tantalizing [48]. The activity of the catalytic
core of SCF, which is formed from the Rbx1 and Cul1 sub-
units, is stimulated by the attachment of ubiquitin-like
protein Nedd8 to conserved lysines in the cullin-homol-
ogy domain of Cul1 [49]. This step invokes recruitment of
E2 enzymes and thus promotes assembly of an active SCF
complex. Conversely, deneddylation of cullins through
the CSN/COP9 signalosome, with its Jab1/CSN5 subunit
directly cleaving off Nedd8, decreases E2 recruitment
[50,51]. In addition, CSN recruits a deubiquitylase,
Ubp12, which counteracts the intrinsic ubiquitin-polym-
erizing activity of SCF [52] Furthermore, deneddylated
cullins are sequestered by inhibitory Cand1 [53,54]. It
was proposed that SCF activity is sustained by dynamic
cycles of assembly and disassembly, where both Cand1
and CSN play an essential negative role [55].
Remarkably, a search for intracellular MIF-binding part-
ners by the yeast two-hybrid system yielded Jab1/CSN5 as
potential candidate [56]. CSN5 is a component of the
COP9/CSN signalosome, a multiprotein complex that
plays essential roles in differentiation and morphogenesis
[57,58]. Not surprisingly, deletion of individual subunits
of the CSN complex is embryonically lethal [59,60]. Also
Jab1-null embryos die soon after implantation due to
impaired proliferation and accelerated apoptosis, and
these defects have been attributed in part to the accumu-
lation and/or impaired degradation of p53, cyclin E, and
p27 [61]. Importantly, Jab1 possesses an intrinsic metal-
loprotease activity, which as mentioned above, targets
SCF complexes and deconjugates Nedd8 from the cullins
[51,58]. Whereas Jab1 recycles neddylated cullins into
more stable unneddylated forms [62], the CSN signalos-
ome can further stabilize the SCF by preventing the autou-
biquitination of substrate-recruiting F-box proteins
[63,64]. However, deneddylated cullins are open to inter-
action with the inhibitory Cand1, which has the capacity
to displace both Skp1 and F-box proteins [53,54]. There-
fore, unbalanced activity of Jab1/CSN5 can directly or
indirectly block ubiquitin-dependent proteolysis [65].
Conversely, MIF binds to Jab1/CSN5 and prevents it from
interacting with proteins targeted by the CSN signalosome
[66] (Fig. 2). Our recent study showed that this negative
regulation of Jab1/CSN5 by MIF is a physiologic require-
ment to sustain optimal composition and activity of SCF
ubiquitin ligases [9].
MIF coordinates the cell cycle with DNA damage 
checkpoints
Cells continuously encounter DNA damage caused either
by replication errors at replication forks or by extracellular
noxae such as ultraviolet and ionizing irradiation. Failure
to properly repair DNA can lead to various disorders,
including enhanced rates of tumor development [67,68].
To protect against such insults to the genome, eukaryotic
organisms have evolved an elaborate signalling network
of p53-dependent and p53-independent checkpoints.
Once the integrity of the genome has been compromised,
checkpoint proteins either prevent or delay initiation of
the next cell cycle phase. Notably, DNA damage check-
point kinases (ATM, ATR, Chk1, Chk2) inhibit the Cdk
machinery, the normal function of which is to coordinateCell Division 2007, 2:22 http://www.celldiv.com/content/2/1/22
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SCF activity is sustained by dynamic cycles of assembly and disassembly Figure 2
SCF activity is sustained by dynamic cycles of assembly and disassembly. (A). DNA damage checkpoint pathways 
feed into the proteolytic degradation of key cell cycle regulators, mediated by SCF, to stop the cell cycle. The scheme indicates 
the elements that make up signal transducers (ATM, ATR, Chk1, Chk2) and effectors (SCF, CSN and 26S proteasome). MIF 
binds to Jab1/CSN5 and prevents it from interacting with proteins targeted by CSN, notably the Cullins. (B). Multi-subunit 
structure of the SCF class of E3 ubiquitin ligases. All SCFs consist of Cullins, Skp1, Rbx1 and F-box proteins which associate to 
form an enzymatically active complex. The posttranslational modification of Cullin (Cul1) by Nedd8 renders SCF active, though 
unstable. The removal of Nedd8 from Cullin is catalyzed by Jab1/CSN5. Following deneddylation of Cullins, Skp1 and F-box 
proteins are replaced by the inhibitory protein Cand1.
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DNA replication and partitioning of the chromosomes
[69] (Fig. 2). The DNA damage response also causes
induction of DNA repair functions, such that cells with
modest damage may survive. However, cells with more
severe damage are induced to undergo apoptosis. Muta-
tions affecting DNA damage pathways allow cell prolifer-
ation under conditions of replication stress [68,70].
Therefore, the DNA damage response is subject to tight
control and is regulated at the level of gene expression,
protein phosphorylation, protein stabilization or degra-
dation. Cancer development frequently selects for loss of
p53 function and hence for loss of the G1 checkpoint
[71]. Mutations compromising DNA damage checkpoints
are also oncogenic [67,70], although they are expected to
activate p53.
One of the key functional targets of DNA-damage check-
point regulation is the Cdc25 protein phosphatase family,
which controls cell cycle progression by regulating the
activity of Cdk2 and Cdk1 kinase complexes [68]. We
found that in MIF-deficient mice, Chk1/Chk2-regulated
checkpoints are uncoupled from proteasomal degrada-
tion of Cdc25A under conditions of DNA damage [9]. The
loss of MIF produced similar dysregulation in the proper
degradation of several other cell cycle regulators such as
Cyclin A2, p27, E2F1 and DP1 [9]. Because MIF binds to
Jab1/CSN5 and prevents it from interacting with proteins
targeted by CSN, notably the cullins, it appears that
absence of this interaction can lead to inappropriate
deneddylating activity of Jab1/CSN5 and therefore to the
ensuing dysfunction of the SCF. Importantly, we showed
that DNA damage induces coordinate activity of the G2M
checkpoint and Cul1-containing SCF complexes. Moreo-
ver, Chk1 delivers a signal that not only marks proteins for
degradation but also activates the SCF (Fig 2). These data
emphasize the importance of downstream effectors of
checkpoint pathways that execute the cell division shut-
off program, namely the SCF. In essence, our results imply
that the G2M checkpoint and the SCF complex form a
functional unit to stop cell cycle progression after DNA
damage [9]. These data also provide an attractive mecha-
nism explaining the MIF-p53 relationship and the role of
MIF in tumor development. Given that MIF plays a key
role in the regulation of Cdc25A, Cdk2 and E2F1/DP1
complexes, which can all induce a strong p53-dependent
antiproliferative response, our data suggest that the
involvement of MIF in p53 function is secondary to p53-
independent mechanisms controlling protein stability,
checkpoint regulation, and the integrity of the genome.
While the loss of MIF expression induces a p53-dependent
proliferative block [23,29], concomitant loss of p53 res-
cues these growth defects, but it comes at the price of
increased tumorigenesis [9]. Accordingly, the tumor phe-
notype of MIF/p53 compound mutant mice entails
defects in the checkpoint response and DNA repair proc-
ess [9].
Conclusion
Until recently, MIF was primarily viewed as a tumor pro-
moter through its signaling activities which inhibit p53-
dependent apoptosis [8,15]. Nowadays, it is well estab-
lished that chronic inflammation increases the risk of can-
cer. The important role of MIF in inflammation indeed
suggests that it is not only promoting existing tumors, but
also likely of great relevance for the initiation of cancer by
chronic inflammatory processes. MIF's mechanism of
action reinforces the functional connection between DNA
damage, genomic instability and cancer. By viewing MIF
as a component of a molecular machine that governs the
cell cycle via activity of the SCF complex, it becomes clear
that MIF-specific effects on tumor initiation and/or devel-
opment will inevitably depend on a variety of parameters,
including tissue-specific and microenvironmental aspects.
Furthermore, it is conceivable that a better understanding
of MIF biology will help to design novel strategies for can-
cer treatment. Clinically relevant examples are tumors
with loss of p53 function, which constitute a substantial
clinical problem due to their poor response to chemother-
apy or irradiation [72]. Indeed, the G2M response elicits
signals that can trigger not only growth arrest or apopto-
sis, but also direct activation of DNA repair networks [73].
Therefore, cancer cells must retain sufficient G2M check-
point function in order to survive adverse conditions that
could further destabilize the genome, causing mitotic
catastrophe and cell death. Accordingly, severe disabling
of G2M signaling is viewed as a possible anticancer strat-
egy [67,68,74]. It is believed that inactivation of G2M
checkpoint function would favor tumor cell death by
enhancing the cytotoxic effect of chemotherapeutic rea-
gents. Evidence supporting the role of MIF in the G2M
response suggests that it could be an attractive target for
therapeutic intervention. Specifically, targeting the MIF-
Jab1/CSN5-SCF interaction may have important implica-
tions, since deregulated SCF plays a fundamental role in
the development and survival of many types of human
malignancies.
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